Inhibikase Therapeutics, Inc (IKT)

Etorro trading 970x250
Inhibikase Therapeutics, Inc (IKT) Logo

About Inhibikase Therapeutics, Inc

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease, and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson’s Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It offers products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia. Address: 3350 Riverwood Parkway, Atlanta, GA, United States, 30339

Inhibikase Therapeutics, Inc News and around…

Latest news about Inhibikase Therapeutics, Inc (IKT) common stock and company :

Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
15 Nov, 2021 Yahoo! Finance

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today reported financial results for the third quarter ended September 30, 2021 and highlighted recent developments.

Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation Alpha-Synuclein Summit
27 Oct, 2021 Yahoo! Finance

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that Dr. Milton Werner, Ph.D., President & Chief Executive Officer of Inhibikase, will participate in the Michael J. Fox Foundation Alpha-Synuclein Summit being held virtually from November 3-4, 2021.

Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009
19 Oct, 2021 Yahoo! Finance

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced dosing of the first Parkinson's patient in its Phase 1b clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson's disease.

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Inhibikase Shares Interim 3-Month Toxicology Studies Data Of Parkinson's Candidate
04 Oct, 2021 FinancialContent

Inhibikase Therapeutics Inc(NASDAQ: IKT) hasannounced interim three-month resultsfrom its ongoing chronic ...

Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease
04 Oct, 2021 Yahoo! Finance

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced interim three-month results from its ongoing chronic toxicology studies of oral IkT-148009 administered in rats and non-human primates (NHPs).

Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy
23 Sep, 2021 Yahoo! Finance

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that the Company has been awarded a $385,388 research grant from the U.S. National Institute of Neurological Disease and Stroke (NINDS), an Institute of the National Institutes of Health (NIH), to evaluate the therapeutic potential of IkT-148009, the Company's lead c-Abl inhibito

Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference
07 Sep, 2021 Yahoo! Finance

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced that Dr. Milton Werner, Ph.D., Chief Executive Officer of Inhibikase, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 13-15, 2021. Details for the presentation are below.

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
16 Aug, 2021 Yahoo! Finance

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent developments.

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
27 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Inhibikase To Start Testing Its Parkinson's Candidate In Patients
26 Jul, 2021 FinancialContent

TheFDA has signed offInhibikase Therapeutics Inc's(NASDAQ: IKT) Phase 1b extension study to evaluate its lead ...

Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients
26 Jul, 2021 Yahoo! Finance

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that, after a review of safety, tolerability and pharmacokinetic data from the Company's Phase 1 clinical trial of IkT-148009 in healthy volunteers, the United States Food and Drug Administration (FDA) has given the Company clearance to begin a Phase 1b extension study to evaluat

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
20 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
09 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
08 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
01 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Wednesday
30 Jun, 2021 FinancialContent

During Wednesday's morning session, 29 stocks hit new 52-week lows. Points of Interest: The largest company by ...

The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
22 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock
18 Jun, 2021 Yahoo! Finance

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced the closing of its previously announced underwritten public offering of 15 million shares of its common stock at a price to the public of $3.00 per share. The gross proceeds to Inhibikase from the public offering, before deducting underwriting discounts and commi

The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs
18 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme
17 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

48 Biggest Movers From Yesterday
17 Jun, 2021 FinancialContent

Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) shares jumped 95.1% to close at $7.98 on Wednesday. Gaucho Group highlighted ...

Mid-Afternoon Market Update: Dow Tumbles Over 300 Points; Federal Reserve Maintains Interest Rates
16 Jun, 2021 FinancialContent

Toward the end of trading Wednesday, the Dow traded down 0.92% to 33,983.29 while the NASDAQ fell 0.68% to 13,977.59. The S&P also ...

Stocks Muted Ahead of Big Fed Announcement
16 Jun, 2021 FinancialContent

Wall Street is holding its collective breath ahead of the conclusion of the Federal Reserve's two-day policy meeting, with stocks reflecting that muted sentiment at midday, as investors await comments from Fed Chairman Jerome Powell.

Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today
16 Jun, 2021 FinancialContent

Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and ...

Mid-Day Market Update: Dow Falls 40 Points; Aprea Therapeutics Shares Surge
16 Jun, 2021 FinancialContent

Midway through trading Wednesday, the Dow traded down 0.12% to 34,259.48 while the NASDAQ rose 0.20% to 14,100.31. The S&P also ...

Inhibikase Therapeutics, Inc (IKT) is a NASDAQ Common Stock listed in , ,

970x250